Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla Evaluates US Portfolio Tucks, Generic Advair Studies Progress

Executive Summary

Alongside a build-up in the US, Cipla is keeping a sharp eye on its “profitability profile” in this market and expects to rationalize products that don’t fit the bill. But it remains on track to establishing a respiratory franchise in key regulated markets, with generic Advair studies moving forward in the US.

Advertisement

Related Content

Sun To Trim US Manufacturing, Over 90 Jobs At Stake
Home Gains Buoy Cipla In Q1 But US Momentum Pivotal
Cipla Sounds The Bugle On US Respiratory Ambition
Walmsley: GSK Is 'Prepared' And 'Ready' For US Advair Generic Launch
Cipla Primes For US Momentum But Seretide Generic Is Slow In UK
Operational Fixes At Cipla But All Eyes On Generic Advair

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100361

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel